Abstract
The most popular current hypothesis is that Alzheimers disease (AD) is caused by aggregates of the amyloid peptide (Aβ), which is generated by cleavage of the Aβ protein precursor (APP) by β-secretase (BACE-1) followed by γ- secretase. BACE-1 cleavage is limiting for the production of Aβ, making it a particularly good drug target for the generation of inhibitors that lower Aβ. A landmark discovery in AD was the identification of BACE-1 (a.k.a. Memapsin-2) as a novel class of type I transmembrane aspartic protease. Although BACE-2, a homologue of BACE-1, was quickly identified, follow up studies using knockout mice demonstrated that BACE-1 was necessary and sufficient for most neuronal Aβ generation. Despite the importance of BACE-1 as a drug target, development has been slow due to the incomplete understanding of its function and regulation and the difficulties in developing a brain penetrant drug that can specifically block its large catalytic pocket. This review summarizes the biological properties of BACE-1 and attempts to use phylogenetic perspectives to understand its function. The article also addresses the challenges in discovering a selective druglike molecule targeting novel mechanisms of BACE-1 regulation.
Keywords: BACE-1, Secretase, Memapsin, Alzheimer, Amyloid, Aspartyl protease
CNS & Neurological Disorders - Drug Targets
Title: Beta-Secretase: Structure, Function, and Evolution
Volume: 7 Issue: 3
Author(s): Chitra Venugopal, Christina M. Demos, K. S. Jagannatha Rao, Miguel A. Pappolla and Kumar Sambamurti
Affiliation:
Keywords: BACE-1, Secretase, Memapsin, Alzheimer, Amyloid, Aspartyl protease
Abstract: The most popular current hypothesis is that Alzheimers disease (AD) is caused by aggregates of the amyloid peptide (Aβ), which is generated by cleavage of the Aβ protein precursor (APP) by β-secretase (BACE-1) followed by γ- secretase. BACE-1 cleavage is limiting for the production of Aβ, making it a particularly good drug target for the generation of inhibitors that lower Aβ. A landmark discovery in AD was the identification of BACE-1 (a.k.a. Memapsin-2) as a novel class of type I transmembrane aspartic protease. Although BACE-2, a homologue of BACE-1, was quickly identified, follow up studies using knockout mice demonstrated that BACE-1 was necessary and sufficient for most neuronal Aβ generation. Despite the importance of BACE-1 as a drug target, development has been slow due to the incomplete understanding of its function and regulation and the difficulties in developing a brain penetrant drug that can specifically block its large catalytic pocket. This review summarizes the biological properties of BACE-1 and attempts to use phylogenetic perspectives to understand its function. The article also addresses the challenges in discovering a selective druglike molecule targeting novel mechanisms of BACE-1 regulation.
Export Options
About this article
Cite this article as:
Venugopal Chitra, Demos M. Christina, Jagannatha Rao S. K., Pappolla A. Miguel and Sambamurti Kumar, Beta-Secretase: Structure, Function, and Evolution, CNS & Neurological Disorders - Drug Targets 2008; 7 (3) . https://dx.doi.org/10.2174/187152708784936626
DOI https://dx.doi.org/10.2174/187152708784936626 |
Print ISSN 1871-5273 |
Publisher Name Bentham Science Publisher |
Online ISSN 1996-3181 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Therapeutic Applications of Mesenchymal Stem Cells: A Comprehensive Review
Current Stem Cell Research & Therapy Nanotechnology Applications for Diffuse Intrinsic Pontine Glioma
Current Neuropharmacology Effects of Histidine-Tag on Recombinant Human Cytochrome P450 3A5 Catalytic Activity in Reconstitution Systems
Drug Metabolism Letters ERRATUM 2
Current Neuropharmacology The Role of B Cells in Multiple Sclerosis: Implications for B-Cell-Targeted Therapy
Current Medicinal Chemistry Antimicrobial Sensitivity Pattern of Bacterial Pathogens in Urinary Tract Infections in South Delhi, India
Reviews on Recent Clinical Trials Telomere/Telomerase System: A New Target of Statins Pleiotropic Effect?
Current Vascular Pharmacology Meet Our Editorial Board Member:
Current Alzheimer Research Cardiovascular Effects Mediated by Imidazoline Drugs: An Update
Cardiovascular & Hematological Disorders-Drug Targets Drug-Related Death Following Release from Prison: A Brief Review of the Literature with Recommendations for Practice
Current Drug Abuse Reviews Functional Effects of Levosimendan in Rat Basilar Arteries In Vitro
Current Neurovascular Research Hormones in the Mentally Disturbed Brain: Steroids and Peptides in the Development and Treatment of Psychopathology
Central Nervous System Agents in Medicinal Chemistry Amyloid PET and MRI in Alzheimers Disease and Mild Cognitive Impairment
Current Alzheimer Research Balancing Antioxidant, Hypolipidemic and Anti-inflammatory Activity in a Single Agent: The Example of 2-Hydroxy-2-Substituted Morpholine, 1,4-Benzoxazine and 1,4-Benzothiazine Derivatives as a Rational Therapeutic Approach against Atherosclerosis
Current Medicinal Chemistry Potential Roles of Selenium and Selenoproteins in the Prevention of Alzheimer's Disease
Current Topics in Medicinal Chemistry Formation of Vesicles Through Solvent Assisted Self-Assembly of Hydrophobic Pentapeptides: Encapsulation and pH Responsive Release of Dyes by the Vesicles
Protein & Peptide Letters Are Anti-Angiogenic Drugs Useful in Neurodegenerative Disorders?
CNS & Neurological Disorders - Drug Targets Inflammatory Biomarkers in AD: Implications for Diagnosis
Current Alzheimer Research Switching to Raltegravir in Virologically Suppressed in HIV-1-Infected Patients: A Retrospective, Multicenter, Descriptive Study
Current HIV Research Societal and Cultural Attitudes to Gout: An Important Consideration in the Successful Management of Gout among Maori in Aotearoa New Zealand
Current Rheumatology Reviews